Advanced Search

ICD-10-PCS code List for Teclistamab Antineoplastic

ICD-10-PCS code List for Teclistamab Antineoplastic is medical classification list by Centers for Medicare and Medicaid Services (CMS).

PCS Tables

PCS CODE

Description

Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8

Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8

Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2

Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8

Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8

Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3

Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5

Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3

Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5

Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5

Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5

Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5

Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9

Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Meropenem-vaborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5

Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9

Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5

Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9

Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9

Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5

Introduction of Imipenem-cilastatin-relebactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5

Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5